90Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates

Zsolt Szakács; Amar Lal; Jorgen Kristensen; Nelli Farkas; Zsombor Ritter; Szabolcs Kiss; Hussain Alizadeh; Anett Balikó

doi:10.1016/j.adro.2021.100882

⁹⁰Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates

Adv Radiat Oncol. 2021 Dec 26;7(5):100882. doi: 10.1016/j.adro.2021.100882. eCollection 2022 Sep-Oct.

Authors

Zsolt Szakács¹, Amar Lal², Jorgen Kristensen³, Nelli Farkas^{4

5}, Zsombor Ritter⁶, Szabolcs Kiss^{4

7}, Hussain Alizadeh¹, Anett Balikó⁸

Affiliations

¹ Division of Hematology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary.
² Tawam Hospital (in affiliation with Johns Hopkins Medicine), Al Ain, United Arab Emirates.
³ Sheikh Khalifa Medical City, Al Tibbiya, Abu Dhabi, United Arab Emirates.
⁴ Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
⁵ Institute of Bioanalysis, Medical School, University of Pécs, Pécs, Hungary.
⁶ Division of Nuclear Medicine, Department of Medical Imaging, Medical School, University of Pécs, Pécs, Hungary.
⁷ Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary.
⁸ Tolna County Balassa János Hospital (in affiliation with Medical School, University of Pécs), Szekszárd, Hungary.

Abstract

Purpose: B-cell non-Hodgkin lymphomas (NHLs) are significant contributors to cancer-related mortality. In this single-arm, retrospective cohort study, we aimed to examine the outcomes of a radioimmunotherapeutic modality, ⁹⁰Y-labeled ibritumomab tiuxetan (⁹⁰YIT) in B-cell NHLs.

Methods and materials: We conducted this study based on data from the United Arab Emirates lymphoma registry. All patients with NHL subjected to ⁹⁰YIT were eligible for inclusion. The country of research lacked a national autologous stem cell transplantation (ASCT) center, but many ASCT-eligible patients received ⁹⁰YIT. We investigated overall survival (OS) and event-free survival (EFS), as well as safety outcomes.

Results: Between 2004 and 2008, 54 of 111 patients with B-cell NHL received radioimmunotherapy. The therapy was applied as first-line treatment in 18 cases (33.3%) and second- or later-line treatment in 36 cases (66.7%). All patients were evaluable for response. The first-line group consisted mainly of follicular lymphoma cases, and 3 of 18 patients died (16.7%) during the follow-up (range, 22-67 months). Median OS was not reached. No progression occurred after treatment (median EFS, 36.5 months [Q₁-Q₃ range, 30.5-44 months]). The second- or later-line group consisted mainly of diffuse large B-cell lymphoma cases, and 3 of 36 patients died (8.3%) during the follow-up (range, 4-68 months). Median OS was not reached. One case of progression was registered (median EFS: 33 months [Q₁-Q₃ range, 30.5-44 months]). ⁹⁰YIT had acceptable short- and long-term safety profiles.

Conclusions: The findings suggest that patients with NHL may benefit from ⁹⁰YIT as salvage treatment if ASCT is not available; however, this should be validated in randomized studies.